SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback
Authors:
- Camila H. CoelhoCCCamila H. Coelho
- Nathaniel BloomNBNathaniel Bloom
- Sydney I. RamirezSRSydney I. Ramirez
- Urvi M. ParikhUPUrvi M. Parikh
- Amy HeapsAHAmy Heaps
- Scott F. SiegSSScott F. Sieg
- Alex GreningerAGAlex Greninger
- Justin RitzJRJustin Ritz
- Carlee MoserCMCarlee Moser
- Joseph J. EronJEJoseph J. Eron
- Judith S. CurrierJCJudith S. Currier
- Paul KlekotkaPKPaul Klekotka
Preprint
Abstract
Therapeutic anti-SARS-CoV-2 monoclonal antibodies (mAbs) have been extensively studied in humans, but the impact on immune memory of mAb treatment during an ongoing immune response has remained unclear. Here, we evaluated the effect of infusion of the anti-SARS-CoV-2 spike receptor binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2–infected individuals. Bamlanivimab treatment skewed the repertoire of memory B cells targeting Spike towards non-RBD epitopes. Furthermore, the relative affinity of RBD memory B cells was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA COVID-19 vaccination, memory B cell differences persisted and mapped to a specific defect in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating human memory B cell responses, both to infection and vaccination. These data indicate that mAb administration can promote alterations in the epitopes recognized by the B cell repertoire, and the single administration of mAb can continue to determine the fate of B cells in response to additional antigen exposures months later. SIGNIFICANCE STATEMENT Evaluating the therapeutic use of monoclonal antibodies during SARS-CoV-2 infection requires a comprehensive understanding of their impact on B cell responses at the cellular level and how these responses are shaped after vaccination. We report for the first time the effect of bamlanivimab on SARS-CoV-2 specific human memory B cells of COVID-19 infected humans receiving, or not, mRNA immunization.Keywords
This publication has 37 references indexed in Scilit:
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodiesCell Host & Microbe, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody RecognitionCell Host & Microbe, 2021
- Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humansScience Translational Medicine, 2020
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerabilityScience, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Germinal center B cells govern their own fate via antibody feedbackJournal of Experimental Medicine, 2013
- Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune ResponseScience, 2011
- Regulation of Antibody Responses via Antibodies, Complement, and Fc ReceptorsAnnual Review of Immunology, 2000
- ACTIVE IMMUNITY PRODUCED BY SO CALLED BALANCED OR NEUTRAL MIXTURES OF DIPHTHERIA TOXIN AND ANTITOXINJournal of Experimental Medicine, 1909